GNPX · Genprex, Inc.

This 8-K discloses a newly granted patent from the Israel Patent Office for Genprex’s REQORSA® in combination with PD-1 antibodies, a development that extends the Company’s existing international patent coverage for this therapeutic approach. While the filing does not disclose financial terms, clinical trial timelines, or regulatory milestones, the grant represents a tangible reinforcement of Genprex’s intellectual property position in a jurisdiction where lung cancer carries significant public health burden — per the filing, lung cancer was the leading cause of cancer death in Israel in 2021. The patent aligns with Genprex’s strategy to protect REQORSA’s use in combination regimens, particularly with established immunotherapies, and builds upon prior grants across nine other jurisdictions. However, no information is provided regarding enforceability, term duration, scope of claims, or linkage to ongoing or planned clinical development — limiting near-term operational or commercial implications. As such, the event signals continued IP progress but does not indicate advancement in clinical, regulatory, or revenue-generating milestones.